Invest in the next phase

DocSWISS-AI – The Decision Cockpit That Eliminates Risk

At TRL 4, DocSWISS-AI — our radiation-tolerant edge-AI vital signs patch — delivers real-time predictive alerts (target ≥95% accuracy) + a unique retraction strategy that eliminates ongoing risk (QoL/performance/safety impact). As the first CRO with space-validated evidence targeting fast-track EMA, it avoids massive follow-up costs (unnecessary interventions, liability claims, preventable deaths) at only ~10% of the avoided expenses.

Market Opportunity

Global medical wearables: €18–20B (2025) → €57B+ by 2030 (CAGR ~17%).


Cross-sector TAM

  • Healthcare: €1.3–7B
  • Defense & Security: €4.7B
  • Space: €1.5–1.7B
  • Industrial Safety: €2–5B
  • Aviation & Mass Events: High-G triage & safety
  • Financial/Insurance & Wellness: €12–14B

Business Model & Traction

  • Revenue Streams: Device (€200–400) + subscription (€15–30/mo) + EuDiPPA brokerage fees.
  • 5-Year Projection: €450–500M cumulative revenue (base case).
  • Break-even: Year 2–3.
  • Current Traction: TRL 4 lab-validated prototype, signed MoU/NDA (EuDiPPA, Digital Health Europe, Prof. C.J. Schilt/VUB), grant pipeline (EU4Health Jan 2026, Horizon Apr 2026, EIC May 2026).

Unique Value Proposition

  • Decision Cockpit: Predictive alerts + retraction strategy eliminates risk exposure.
  • First-in-Class: Radiation-hardened (>100–300 krad) + sovereign EU data (Rust-based, citizen-owned) + space-validated fast-track EMA pathway.
  • ROI for Clients: Avoids billions in follow-up costs/deaths at ~10% expense.

Team & Expertise

Lean startup with part-time domain experts (high-caliber, low-cost, scalable to full-time):

  • Dr. Johannes Petrus Maria (John) Wubbe – President & Founder (vision/strategy).
  • Menno Nijdam – COO (operations/execution).
  • Guilherme (Gonçalo) Monteiro Ferreira – Market Access & Pharma (EMA/payer strategy).
  • Erwin Wolff – CTO (Rust/ICT stack).
  • Prof. C.J. Schilt (VUB) – Grant/University Coordinator (ethics/governance).

Consortium & Partners

  • Signed MoU/NDA: EuDiPPA (patient brokerage), Digital Health Europe (Partnering 4 Human Health & Performance, Improving Outcomes & Impacts), Prof. C.J. Schilt (VUB – grant/university coordinator).
  • Targeted Discussions: Universities (NL/CH/BE/DE), technical validation, European-level space agencies.

Funding Ask & Use of Funds

  • Total 2026–2028: €8–12M (70–80% grants + equity/debt).
  • Seed/Bridge: €2–5M equity/debt (post-grant traction).
  • Use of Funds: Prototype scaling, pilots (TRL 5–6), EMA dossier, team growth.
  • Exit Target: Medtech/defense acquisition (2029–2032).

Why Invest Now?

  • TRL 4 → pilots (low entry risk, high upside).
  • Wearables boom + EHDS push + dual-use demand.
  • Retraction eliminates risk (first in class).
  • Space-validated EMA fast-track.
  • Lean model + strong grant pipeline.

Next Steps

Download the full Investor Deck or schedule a call:
Email: john.wubbe@doc.swiss
Phone: +41 79 946 38 43

Thank You

DocSWISS AG – Zurich, Switzerland